Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer

Genes Chromosomes and Cancer

Volumn 49, Issue 7, 2010, Pages 585-595

  Kim, Sunghoon ^a   Cho, HanByoul ^a   Nam, Eun Ji ^a   Kim, Sang Wun ^a   Kim, Young Tae ^a   Park, Yong Won ^a   Kim, Bo Wook ^a   Kim, Jae Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN; MESSENGER RNA; PHOSPHOPROTEIN; PHOSPHOPROTEIN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; STRESS;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PROTEOMICS; RNA, MESSENGER;

EID: 77953193040     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20769     Document Type: Article

References (39)

1. Anderson KS, LaBaer J. 2005. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4:1123-1133. (Pubitemid 41208670)
2. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. 1994. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480-487. (Pubitemid 24268085)
3. Averna M, Stifanese R, De Tullio R, Salamino F, Pontremoli S, Melloni E. 2008. In vivo degradation of nitric oxide synthase (NOS) and heat shock protein 90 (HSP90) by calpain is modulated by the formation of a NOS-HSP90 heterocomplex. FEBS J 275:2501-2511.
4. Bast RC, Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. 1998. CA 125: The past and the future. Int J Biol Markers 13: 179-187.
5. Benedet JL, Bender H, Jones H, III, Ngan HY, Pecorelli S. 2000. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209-262.
6. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. 2006. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66:1181-1190.
7. Cho H, Kang ES, Hong SW, Oh YJ, Choi SM, Kim SW, Kim SH, Kim YT, Lee KS, Choi YK, Kim JH. 2008. Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line. Mol Cell Biochem 319:189-201.
8. Cho H, Kim JH. 2009. Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 57:513-521.
9. Cho H, Lim BJ, Kang ES, Choi JS, Kim JH. 2009. Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med 218:129-139.
10. Erkanli A, Taylor DD, Dean D, Eksir F, Egger D, Geyer J, Nelson BH, Stone B, Fritsche HA, Roden RB. 2006. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res 66:1792-1798. (Pubitemid 43259965)
11. Erlich RB, Kahn SA, Lima FR, Muras AG, Martins RA, Linden R, Chiarini LB, Martins VR, Moura Neto V. 2007. STI1 promotes glioma proliferation through MAPK and PI3K pathways. Glia 55:1690-1698.
12. Fernandez-Madrid F, Tang N, Alansari H, Granda JL, Tait L, Amirikia KC, Moroianu M, Wang X, Karvonen RL. 2004. Autoantibodies to Annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res 64:5089-5096. (Pubitemid 39006524)
13. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. 2008. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 14:764-771. (Pubitemid 351231158)
14. Goeb V, Thomas-L'Otellier M, Daveau R, Charlionet R, Fardellone P, Le Loet X, Tron F, Gilbert D, Vittecoq O. 2009. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 11:R38.
15. Jacobs IJ, Menon U. 2004. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3:355-366. (Pubitemid 38702089)
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
17. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410. (Pubitemid 37187270)
18. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. 2003. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782-4791. (Pubitemid 37323281)
19. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. 2002. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671-1679. (Pubitemid 34289219)
20. Liang P, Averboukh L, Keyomarsi K, Sager R, Pardee AB. 1992. Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. Cancer Res 52:6966-6968.
21. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL. 1996. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680.
22. Miao RQ, Fontana J, Fulton D, Lin MI, Harrison KD, Sessa WC. 2008. Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler Thromb Vasc Biol 28:105-111.
23. Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA, Khan IU, Gupta RK, Cho-Chung YS. 2006. Autoantibody cancer biomarker: Extracellular protein kinase A. Cancer Res 66:8971-8974. (Pubitemid 44521113)
24. Nolen B, Winans M, Marrangoni A, Lokshin A. 2009. Aberrant tumor- associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay. J Immunol Methods 344:116-120.
25. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. 1998. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143:901-910.
26. Pearl LH. 2005. Hsp90 and Cdc37 - A chaperone cancer conspiracy. Curr Opin Genet Dev 15:55-61.
27. Sato S, Fujita N, Tsuruo T. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832-10837.
28. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ. 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76:652-658.
29. Shibusa T, Shijubo N, Abe S. 1998. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4:1483-1487.
30. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354.
31. Tan EM, Zhang J. 2008. Autoantibodies to tumor-associated antigens: Reporters from the immune system. Immunol Rev 222:328-340. (Pubitemid 351430373)
32. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. 1995. Serial analysis of gene expression. Science 270:484-487.
33. Wang T, Chao A, Huang H, Lai C. 2008. Proteomic identification of stress-induced phosphoprotein (STIP-1) as a potential biomarker for human ovarian cancer. In: Proceedings of 2008 ASCO Annual Meeting. Chicago, USA.
34. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. 2005. Autoantibody signatures in prostate cancer. N Engl J Med 353:1224-1235.
35. Whitesell L, Lindquist SL. 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
36. Zalcman G, Schlichtholz B, Tredaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A, Soussi T. 1998. Monitoring of p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment. Clin Cancer Res 4:1359-1366. (Pubitemid 28265217)
37. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. 1997. Gene expression profiles in normal and cancer cells. Science 276:1268-1272. (Pubitemid 27227367)
38. Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC, Liu BC. 2003. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98:2576-2582. (Pubitemid 37509520)
39. Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, Zhang XG, Gao X, Hu W, Yen Y, Kernstine KH. 2008. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 10:R40.